Pfizer faces a challenging revenue outlook for 2026 after projecting annual sales of $59.5–62.5 billion, with the midpoint below 2025’s $62 billion forecast. The company anticipates a combined $3 billion hit from declining COVID-19 product sales and the loss of exclusivity on key drugs. In particular, the blockbuster anticoagulant Eliquis will lose patent protection next year, and oncology agents Ibrance and Xtandi follow in 2027. With no late-stage candidates poised to fully replace this revenue gap, investors will closely watch Pfizer’s cost-saving initiatives and potential licensing or acquisition strategies to stabilize near-term cash flow.

Despite stock price volatility over the past three years, Pfizer’s forward dividend yield stands at approximately 6.8%, one of the highest among S&P 500 healthcare names. Management has labeled the payout a “sacred cow,” emphasizing its commitment to maintaining the distribution. Free cash flow in 2025 covered the dividend by a comfortable margin, and conservative payout ratios suggest the company can sustain its current level of income distribution even if top-line growth remains flat. Income-oriented investors may view the high yield as a hedge against share price stagnation across 2026.

Investors are pinning hopes on clinical readouts from obesity and metabolic programs acquired with Metsera in late 2025. Phase 2b Vesper-2 and Vesper-3 trials of MET-097i in type 2 diabetes are expected in early 2026, following encouraging Vesper-1 data. Success could unlock entry into a multi-billion-dollar obesity market and reposition Pfizer’s growth trajectory. The stock trades at a forward price-to-earnings multiple near 8.5, below sector averages, suggesting that any positive trial outcomes or favorable regulatory news may trigger a meaningful re-rating. However, investors remain cautious given the looming patent expirations over the next two years.